News Boehringer drug for brain fog in schizophrenia fails trial Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.
R&D Partner Content Register Now for the AAPS National Biotechnology Conference The AAPS National Biotechnology Conference uncovers the trends driving today’s biotech markets.
News Keros pulls study of Winrevair rival after safety signal Adverse events have led Keros to abandon a phase 2 trial of pulmonary arterial hypertension drug cibotacept, a would-be rival to MSD's Winrevair.
News Sling shoots at thyroid eye disease with its oral therapy Amgen's thyroid eye disease blockbuster Tepezza, given by infusion, is facing competition from an oral alternative from Sling Therapeutics.
News Bayer gains ground in two-fronted Parkinson's offensive Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.
R&D The intricacies of effectively transitioning active clinical... European Union lawmakers designed EU Clinical Trial Regulation 536/2014 to heighten interest within the healthcare industry for planning and conducting clinical trials in the
News J&J's oral IL-23 drug backed for psoriasis in EU J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.